Filing Details
- Accession Number:
- 0001048477-24-000112
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2024-05-30 18:18:05
- Reporting Period:
- 2024-05-28
- Accepted Time:
- 2024-05-30 18:18:05
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1048477 | Biomarin Pharmaceutical Inc | BMRN | Pharmaceutical Preparations (2834) | 680397820 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1380710 | Eric George Davis | C/O Biomarin Pharmaceutical Inc. 770 Lindaro Street San Rafael CA 94901 | Evp, Chief Legal Officer | No | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2024-05-28 | 40,850 | $63.10 | 97,007 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2024-05-28 | 38,071 | $74.46 | 58,936 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2024-05-28 | 2,779 | $75.29 | 56,157 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Stock Option (Right to Buy Common Stock) | Disposition | 2024-05-28 | 40,850 | $0.00 | 40,850 | $63.10 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 0 | 2014-12-04 | 2024-06-30 | No | 4 | M | Direct |
Footnotes
- Trade made pursuant to a 10b5-1 plan executed on September 13, 2023.
- The price in column 4 is the weighted average price. The purchase price actually received ranged from $74.12 to $74.99. The reporting person shall provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price.
- The price in column 4 is the weighted average price. The purchase price actually received ranged from $75.00 to $75.735. The reporting person shall provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price.
- Reflects the number of options outstanding after the transactions from this specific stock option grant.
Billionaire Hedge Funds
